Contract facts
UnrestrictedPartner Therapeutics: the Overall Objective of This Contract Is to Confirm Leukine Safety in Sepsis Patients, Inform Op… is a federal Unrestricted award for Barda - Aspr / Daappo / Barda Dcma held by Partner Therapeutics, Inc. Estimated value $13.7M ($13M obligated). Current period of performance ends Mar 31, 2028 (potential Sep 30, 2028). Last award drew 100 bidders. Place of performance: LEXINGTON MA. Related solicitation EZ-BAA-22-100-SOL-00003.
Partner therapeutics: the overall objective of this contract is to confirm leukine safety in sepsis patients, inform optimal leukine dosing, explore leukine efficacy, as well as advance development of monocyte human leukocyte antigen-dr (mhla-dr) as. Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Mar 31, 2028 (511 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Oct 1, 2026.
Want the durability read on 75A50124C00061? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordPartner Therapeutics, Inc — $147.4M obligated across 9 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50124C00061?
75A50124C00061 (Partner therapeutics: the overall objective of) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $13.7M, currently held by Partner Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50124C00061?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50124C00061 to Partner Therapeutics, Inc (potential $13.7M).
Who is the incumbent on 75A50124C00061?
Partner Therapeutics, Inc is the incumbent with $147.4M across 9 related awards in SCOUT’s public footprint. The current period of performance ends Mar 31, 2028.
When does Partner Therapeutics, Inc’s 75A50124C00061 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 31, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75A50124C00061? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.